Prediction of Anthracycline-Induced Left Ventricular Dysfunction by Cardiac Troponins

被引:4
|
作者
Thigpen, S. Calvin
Geraci, Stephen A.
机构
[1] Univ Mississippi, Sch Med, Dept Med, Div Hematol & Oncol, Jackson, MS 39216 USA
[2] Univ Mississippi, Sch Med, Dept Med, Div Cardiovasc Dis, Jackson, MS 39216 USA
关键词
anthracycline; chemotherapy; heart failure; troponin; HIGH-DOSE CHEMOTHERAPY; PEGYLATED LIPOSOMAL DOXORUBICIN; INDUCED CARDIOTOXICITY; CANCER-PATIENTS; LYMPHOMA; MARKER; ADULTS;
D O I
10.1097/SMJ.0b013e3182749006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Evidence suggests prognostic utility of troponin (Tn) serum concentrations for a variety of conditions. We sought to determine whether elevated concentrations early after anthracycline chemotherapy predict the development of left ventricular systolic dysfunction in adult patients with cancer. PubMed/MEDLINE searches identified original reports that assessed cardiac TnI or TnT within 5 days of anthracycline chemotherapy and evaluated left ventricular systolic function after treatment for review. Ten reports qualified for review. Four studies indicated a significant relation between elevated Tn and subsequent left ventricular systolic dysfunction. One study that enrolled patients actively receiving anthracyclines and others who had previously received anthracyclines also demonstrated a significant relation. The remaining five reports identified no such relation. Heterogeneity in experimental methods, sampling times, and handling of confounders was significant between positive and negative studies. The present evidence is insufficient to suggest that Tns are reliable predictors of left ventricular dysfunction in patients with cancer. These data suggest, however, that larger prospective studies using frequent scheduled Tn measurement with adjustment for confounding factors could determine the predictive value of Tns in this setting.
引用
收藏
页码:659 / 664
页数:6
相关论文
共 50 条
  • [21] Biomarker Determinants of Early Anthracycline-Induced Left Ventricular Dysfunction in Breast Cancer: A Systematic Review and Meta-Analysis
    Stavroula L. Kastora
    Tiberiu A. Pana
    Yusuf Sarwar
    Phyo K. Myint
    Mamas A. Mamas
    Molecular Diagnosis & Therapy, 2022, 26 : 369 - 382
  • [22] Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer:: A comparative study with echocardiography and multigated radionuclide angiography
    Çorapçioglu, F
    Sarper, N
    Berk, F
    Sahin, T
    Zengin, E
    Demir, H
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (01) : 71 - 80
  • [23] Cardiac MRI assessment of anthracycline-induced cardiotoxicity
    Mabudian, Leila
    Jordan, Jennifer H.
    Bottinor, Wendy
    Hundley, W. Gregory
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [24] Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
    Visscher, Henk
    Ross, Colin J. D.
    Rassekh, S. Rod
    Barhdadi, Amina
    Dube, Marie-Pierre
    Al-Saloos, Hesham
    Sandor, George S.
    Caron, Huib N.
    van Dalen, Elvira C.
    Kremer, Leontien C.
    van der Pal, Helena J.
    Brown, Andrew M. K.
    Rogers, Paul C.
    Phillips, Michael S.
    Rieder, Michael J.
    Carleton, Bruce C.
    Hayden, Michael R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1422 - 1428
  • [25] Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy
    Patel, Divyang
    Kumar, Anirudh
    Moennich, Laurie Ann
    Trulock, Kevin
    Nemer, David M.
    Donnellan, Eoin
    Il'Giovine, Zachary J.
    Martyn, Trejeeve
    Callahan, Thomas D.
    Hussein, Ayman A.
    Tarakji, Khaldoun G.
    Kanj, Mohamed
    Cantillon, Daniel J.
    Baranowski, Bryan
    Starling, Randall C.
    Tang, W. H. Wilson
    Wazni, Oussama M.
    Varma, Niraj
    Wilkoff, Bruce L.
    Rickard, John
    HEART, 2022, 108 (04) : 274 - 278
  • [26] Anthracycline-induced cardiac toxicity: A clinical review
    Abbas, Adil Abdelhameed
    AlAzmi, Aeshah Abdu Mubarak
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 465 - 475
  • [27] Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation
    Guha, Avirup
    Caraballo, Cesar
    Jain, Prantesh
    Miller, P. Elliott
    Owusu-Guha, Jocelyn
    Clark, Katherine A. A.
    Velazquez, Eric J.
    Ahmad, Tariq
    Baldassarre, Lauren A.
    Addison, Daniel
    Weintraub, Neal L.
    Desai, Nihar R.
    ESC HEART FAILURE, 2021, 8 (04): : 2866 - 2875
  • [28] Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock
    ver Elst, KM
    Spapen, HD
    Nguyen, DN
    Garbar, C
    Huyghens, LP
    Gorus, FK
    CLINICAL CHEMISTRY, 2000, 46 (05) : 650 - 657
  • [29] Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: The need for evidence
    van Dalen, EC
    van der Pal, HJH
    van den Bos, C
    Caron, HN
    Kremer, LCM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3377 - 3377
  • [30] Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
    Murabito, Alessandra
    Hirsch, Emilio
    Ghigo, Alessandra
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7